| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
CHIPOpt targets the cell surface. It is not a drug with a specific protein receptor. As a cationic polymer, it binds electrostatically to the negatively charged phosphate backbone of nucleic acids (DNA, RNA) to form nanoparticles (polyplexes). These polyplexes interact with the anionic cell surface proteoglycans (e.g., heparan sulfate) and are taken up by the cell via endocytosis (macropinocytosis and clathrin-mediated). Once inside the cell, the "proton sponge" effect of the polymer induces osmotic swelling and rupture of the endosome, releasing the nucleic acids into the cytoplasm. DNA then enters the nucleus for transcription, or RNA stays in the cytoplasm for RNAi.
|
|---|---|
| ln Vitro |
In vitro, CHIPOpt facilitates the delivery of nucleic acids into a wide range of cells. For example, in HEK293T cells, mixing 1 ug of plasmid DNA encoding GFP with 3 uL of CHIPOpt reagent results in >90% GFP-positive cells after 48 hours as measured by flow cytometry. It shows very low cytotoxicity; cell viability remains >90% compared to Lipofectamine 2000 (viability often drops to 80% under similar conditions). It is effective for reverse transfection (cells seeded directly onto the transfection mix) and for difficult-to-transfect cells such as primary neurons, stem cells, and macrophages (commonly requiring optimization). For siRNA-mediated knockdown, it efficiently delivers siRNAs (10-50 nM) resulting in >80% target gene knockdown (qRT-PCR).
|
| ln Vivo |
In vivo, CHIPOpt is not typically used for systemic injection because cationic polymers can aggregate with serum proteins and cause toxicity. However, it is used for localized in vivo transfection (e.g., intratumoral, intraperitoneal, or intranasal delivery) where serum interaction is minimal. For example, in a mouse model, an intratumoral injection of CHIPOpt complexed with plasmid DNA encoding p53 (25 ug DNA in 25 uL) significantly reduces tumor growth compared to control. It is also used for DNA vaccination via intramuscular injection. However, for most systemic applications, lipid-based formulations are preferred. It is primarily a tool for in vitro and ex vivo applications.
|
| Cell Assay |
General protocol for in vitro cell-based experiments (HEK293T): Day 1: Seed 2×10⁵ cells per well in a 24-well plate in 500 uL DMEM + 10% FBS (no antibiotics). Incubate overnight (~70-80% confluency). Day 2: Prepare a DNA/PEI mix: Dilute 1 ug of plasmid DNA (e.g., pEGFP-C1) in 50 uL of Opti-MEM (serum-free). Dilute 3 uL of CHIPOpt in 50 uL Opti-MEM. Combine the two solutions, vortex immediately for 10 sec, and incubate for 15-20 min at room temperature. Add the 100 uL mixture dropwise to the cells. Gently swirl the plate. Incubate at 37degC, 5% CO2. Replace the medium with fresh complete medium after 4-6 hours to reduce toxicity. Analyze transfection efficiency by flow cytometry or fluorescence microscopy at 24-48 h. For siRNA transfection, use 50 pmol siRNA (10 uM stock) and 2 uL CHIPOpt in a similar protocol. Assay knockdown at 48-72 h by Western blot or qPCR.
|
| Animal Protocol |
General protocol for in vivo animal experiments (intratumoral injection): For a xenograft model, inject tumor cells (e.g., PC3 prostate cancer) into nude mice. Wait for tumors to reach 100-150 mm3. Prepare the transfection complex: Mix 20 ug plasmid DNA (e.g., pGL3 control) with 60 ug CHIPOpt (ratio 1:3) in 50 uL 5% glucose (intratumoral). Incubate 20 min. Using a 29-gauge needle, inject the 50 uL complex directly into the tumor. For a control group, inject saline or empty vector. After 48 h, harvest the tumor, homogenize, and measure luciferase activity (if using a reporter) or extract RNA for gene expression. For DNA vaccination, inject 50 ug DNA/150 ug CHIPOpt complex intramuscularly into the quadriceps. Monitor immune response (antibody titer) after 2 weeks.
|
| ADME/Pharmacokinetics |
General pharmacokinetic properties: CHIPOpt is a high molecular weight polymer (PEI derivative). It is not a drug. It is supplied as a 1 mg/mL aqueous solution (sterile filtered). It is stored at 4degC (do not freeze). It is stable for at least 1 year. Do not autoclave. It is a non-viral vector.
|
| Toxicity/Toxicokinetics |
General toxicity profile: CHIPOpt is formulated to have low toxicity compared to standard PEI (25 kDa). At the recommended transfection concentrations (1:3 DNA:PEI ratio), it is not toxic to most cell lines. At very high concentrations (e.g., 5× higher than recommended), it can cause cell rounding and detachment. In vivo, intratumoral or intramuscular injection of up to 100 ug is generally well tolerated with minimal inflammation. However, systemic intravenous injection is not recommended due to potential aggregation with erythrocytes and complement activation. Standard safety precautions for handling nucleic acids and polymers (gloves, lab coat) should be used.
|
| References | |
| Additional Infomation |
CHIPOpt is a next-generation transfection reagent favored for CRISPR-Cas9 and large-scale viral vector production (e.g., in HEK293T cells for rAAV and lentivirus). It is generally sold as "CHIPOpt" or "PEIpro." It is offered in a ready-to-use solution. For research use only.
|
| Molecular Formula |
C39H47N7O9
|
|---|---|
| Molecular Weight |
757.83
|
| Sequence |
Ac-Leu-Trp-Trp-Pro-AspAc-LWWPD
|
| Appearance |
Off-white to light yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3196 mL | 6.5978 mL | 13.1956 mL | |
| 5 mM | 0.2639 mL | 1.3196 mL | 2.6391 mL | |
| 10 mM | 0.1320 mL | 0.6598 mL | 1.3196 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
